Compare · CERS vs MDLN
CERS vs MDLN
Side-by-side comparison of Cerus Corporation (CERS) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $49.77B, about 129.7x CERS ($383.7M).
- MDLN has been more active in the news (25 items in the past 4 weeks vs 8 for CERS).
- MDLN has more recent analyst coverage (25 ratings vs 4 for CERS).
- Company
- Cerus Corporation
- Medline Inc.
- Price
- -
- -
- Market cap
- $383.7M
- $49.77B
- 1M return
- -
- +7.21%
- 1Y return
- -
- -7.15%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1997
- 2025
- News (4w)
- 8
- 25
- Recent ratings
- 4
- 25
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
Latest CERS
- Cerus Corporation to Participate in Upcoming Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by Cerus Corporation
- Cerus Corporation to Participate in the 17th Annual Craig-Hallum Alpha Select Conference
- SEC Form S-3 filed by Cerus Corporation
- SEC Form 10-Q filed by Cerus Corporation
- Cerus Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cerus Corporation Announces Third Quarter 2026 Financial Results
- Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells
- Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026
- Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
Latest MDLN
- Large owner Cp Circle Ml Holdco Gp, Llc converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Carlyle Mozart Coinvestment Holdings, L.P. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 7,570,214 shares and disposed of 7,570,214 units of Class B Common Stock (SEC Form 4)
- Large owner Tc Group Cayman Investment Holdings, L.P. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Carlyle Group Inc. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. converted options into 12,128,729 shares and disposed of 12,128,729 units of Class B Common Stock (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. converted options into 7,570,214 shares and disposed of 7,570,214 units of Class B Common Stock (SEC Form 4)
- SEC Form 424B4 filed by Medline Inc.
- Medline Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Medline launches right-sized Ranpak packaging solutions in two key distribution centers